Market Overview

Despite A Downgrade, Vetr Still Bullish On Vertex

Despite A Downgrade, Vetr Still Bullish On Vertex
Related VRTX
Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market
Earnings Scheduled For October 25, 2017

On Wednesday, the Vetr crowd downgraded its rating of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from its previous standing of 4.5 stars (Strong Buy) issued earlier this week, to four stars (Buy). Crowd confidence in Vertex is still overwhelmingly positive, with 100 percent of Vetr users bullish toward the stock.

Following last week's reaction to President-elect Donald Trump's comments on lowing drug prices, Vertex's price experienced slight fluctuation, but no monumental change.

However, the post-election biotech bump has certainly settled into a more standard formation. By 1 p.m. on Wednesday, Vertex was hovering at around $77.30, pretty close to its price early in November.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $85.33, which is well below the average analyst price of $108.68. Less than 2 percent of Vetr users are holding Vertex on their watch-lists.

Latest Ratings for VRTX

Sep 2017DA DavidsonInitiates Coverage OnBuy
Sep 2017RBC CapitalInitiates Coverage OnOutperform
Jul 2017CitigroupMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Donald Trump VetrBiotech Downgrades Crowdsourcing Markets Analyst Ratings Trading Ideas


Related Articles (VRTX)

View Comments and Join the Discussion!

Partner Center